Evidence map›Paper›PMID 35648235›Full record

ArticleCellular and molecular life sciences : CMLS2022

Consequences of the Hsp110DE9 mutation in tumorigenesis and the 5-fluorouracil-based chemotherapy response in Msh2-deficient mice.

Kathleen Noel, A 'dem Bokhari, Romane Bertrand, Florence Renaud, Pierre Bourgoin, Romain Cohen, Magali Svrcek, Anne-Christine Joly, Alex Duval, Ada Collura

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Kathleen NoelSorbonne Université, UPMC Univ Paris 06, INSERM, UMRS 938, SIRIC CURAMUS, Equipe Instabilité Des Microsatellites Et Cancer, Equipe Labellisée Par La Ligue Contre Le Cancer, Centre de Recherche Saint Antoine, 75012, Paris, France.
A 'dem BokhariSorbonne Université, UPMC Univ Paris 06, INSERM, UMRS 938, SIRIC CURAMUS, Equipe Instabilité Des Microsatellites Et Cancer, Equipe Labellisée Par La Ligue Contre Le Cancer, Centre de Recherche Saint Antoine, 75012, Paris, France.
Romane BertrandSorbonne Université, UPMC Univ Paris 06, INSERM, UMRS 938, SIRIC CURAMUS, Equipe Instabilité Des Microsatellites Et Cancer, Equipe Labellisée Par La Ligue Contre Le Cancer, Centre de Recherche Saint Antoine, 75012, Paris, France.
Florence RenaudSorbonne Université, UPMC Univ Paris 06, INSERM, UMRS 938, SIRIC CURAMUS, Equipe Instabilité Des Microsatellites Et Cancer, Equipe Labellisée Par La Ligue Contre Le Cancer, Centre de Recherche Saint Antoine, 75012, Paris, France.
Pierre BourgoinSorbonne Université, UPMC Univ Paris 06, INSERM, UMRS 938, SIRIC CURAMUS, Equipe Instabilité Des Microsatellites Et Cancer, Equipe Labellisée Par La Ligue Contre Le Cancer, Centre de Recherche Saint Antoine, 75012, Paris, France.
Romain CohenSorbonne Université, UPMC Univ Paris 06, INSERM, UMRS 938, SIRIC CURAMUS, Equipe Instabilité Des Microsatellites Et Cancer, Equipe Labellisée Par La Ligue Contre Le Cancer, Centre de Recherche Saint Antoine, 75012, Paris, France.
Magali SvrcekSorbonne Université, UPMC Univ Paris 06, INSERM, UMRS 938, SIRIC CURAMUS, Equipe Instabilité Des Microsatellites Et Cancer, Equipe Labellisée Par La Ligue Contre Le Cancer, Centre de Recherche Saint Antoine, 75012, Paris, France.
Anne-Christine JolyUPAC and C (Unité De Préparation Des Anticancéreux Et Contrôle), Saint Antoine Hospital, AP-HP, Paris, France.
Alex DuvalSorbonne Université, UPMC Univ Paris 06, INSERM, UMRS 938, SIRIC CURAMUS, Equipe Instabilité Des Microsatellites Et Cancer, Equipe Labellisée Par La Ligue Contre Le Cancer, Centre de Recherche Saint Antoine, 75012, Paris, France.
Ada ColluraSorbonne Université, UPMC Univ Paris 06, INSERM, UMRS 938, SIRIC CURAMUS, Equipe Instabilité Des Microsatellites Et Cancer, Equipe Labellisée Par La Ligue Contre Le Cancer, Centre de Recherche Saint Antoine, 75012, Paris, France. ada.collura@inserm.fr.ORCID http://orcid.org/0000-0003-0496-1768
Inserm · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heat shock proteins (HSPs) play oncogenic roles in human tumours. We reported a somatic inactivating mutation of HSP110 (HSP110DE9) in mismatch repair-deficient (dMMR) cancers displaying microsatellite instability (MSI) but did not assess its impact. We evaluated the impact of the Hsp110DE9 mutation on tumour development and the chemotherapy response in a dMMR knock-in mouse model (Hsp110DE9

Indexed as

FluorouracilHSP110 Heat-Shock ProteinsNeoplasmsAnimalsCarcinogenesisMiceMicrosatellite InstabilityMutationFluorouracilHSP110 Heat-Shock Proteins5-FU chemotherapyHsp110Microsatellite instabilityMMR deficiencyMouse model

Identifiers

PMID35648235
PMCPMC11072706
OpenAlexW4281635894

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.